In this file photo taken on November 17, 2020, an illustration picture shows vials with COVID-19 vaccine stickers attached and syringes, with the logo of the University of Oxford and its partner British pharmaceutical company AstraZeneca.
December 8, 2020
Oxford/Astra first to publish final-stage vaccine trial results
PARIS, France (AFP) — Oxford University and AstraZeneca became the first COVID-19 vaccine makers to publish final-stage clinical trial results in a scientific journal Tuesday, clearing a key hurdle in the global race to develop safe and effective drugs for the new coronavirus.
The study published in the respected Lancet medical journal confirmed that the vaccine works in an average 70 per cent of cases, with efficacy of 62 per cent for those given two full doses, and of 90 per cent in those given a half then a full dose.
The results are the “first full peer-reviewed efficacy results” published for a COVID-19 vaccine, the Lancet said.
